Verona Pharma's VRNA short percent of float has fallen 11.62% since its last report. The company recently reported that it ...

Verona Pharma (VRNA) is showing exceptional technical strength, hitting a new high in morning trading on June 24. ・The stock has a 100% technical “Buy” signal via Barchart. ・The stock has surged 515% ...

TimesSquare Capital Management, an equity investment management company, released its “U.S. Small Cap Growth Strategy” ...

Verona Pharma plc (NASDAQ:VRNA) is one of the 10 biotech stocks screaming a buy. On June 17, Roth Capital increased its price ...

Verona Pharma's Ohtuvayre launch drives rapid growth and global expansion. Read about the VRNA stock's Q1 results, analyst ...

Verona Pharma plc (NASDAQ:VRNA) is among the 10 Best Growth Stocks Under $100 to Buy Now. Analysts at Jefferies have raised ...

Verona Pharma, now valued at $7.65 billion, has been expanding its sales force, with 30 new representatives set to start in July. This will bring the total sales team to approximately 120 people ...

Verona Pharma plc (NASDAQ:VRNA) extended its rally for an eighth straight day on Tuesday, adding 6.37 percent to end at $73.21 apiece after the company posted an impressive earnings performance ...

Celebrations may be in order for Verona Pharma plc (NASDAQ:VRNA) shareholders, with the analysts delivering a significant upgrade to their statutory estimates for the company. The analysts have ...

Below, we present a snapshot of the trends in volume and open interest for calls and puts across Verona Pharma's significant trades, within a strike price range of $60.0 to $65.0, over the past month.

Verona Pharma plc (NASDAQ:VRNA – Get Free Report) has earned an average rating of “Buy” from the seven brokerages that are presently covering the firm, Marketbeat reports.Six equities ...

Verona Pharma (NASDAQ:VRNA – Free Report) had its price objective increased by HC Wainwright from $60.00 to $75.00 in a report issued on Friday,Benzinga reports.